Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Open-Label, Parallel Group, Multicenter, Extension Study Evaluating the Long-Term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa

NCT04901195 is registered in ClinicalTrials.gov with UCB Biopharma SRL as lead sponsor.

NCT NCT04901195
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04901195 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Open-Label, Parallel Group, Multicenter, Extension Study Evaluating the Long-Term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa
Lead sponsor
UCB Biopharma SRL
Phase
Phase 3
Overall status
Completed
Start date
May 27, 2021
Completion date
July 22, 2026
Enrollment
658 (actual)
Sites
145

Conditions

As the registry lists them; a condition with its own page is linked.

hidradenitis suppurativa